Picture of Organigram Global logo

OGI — Organigram Global News Story

0.000.00%
ca flag iconLast trade - 00:00
HealthcareAdventurousSmall CapTurnaround

Canada's Organigram Q3 revenue beats on Sanity acquisition; CFO to exit

Canada's Organigram Q3 revenue beats on Sanity acquisition; CFO to exit


Overview

  • Canada cannabis producer's fiscal Q3 net revenue rose 49% yr/yr, beating analyst expectations

  • Adjusted EBITDA more than doubled yr/yr, reflecting Sanity Group acquisition and operational gains

  • Company attributed record results to Sanity Group acquisition and improved Canadian operations

  • “I would also like to recognize Paolo De Luca, who will be departing Organigram after nine years of exceptional leadership and service," said James Yamanaka, Chief Executive Officer


Outlook

  • Organigram expects full-year net revenue to exceed C$350 mln

  • Company anticipates adjusted gross margin and adjusted EBITDA to surpass fiscal 2025 levels

  • Organigram expects positive free cash flow in Q4 despite modestly negative free cash flow for the full year


Result Drivers

  • SANITY GROUP ACQUISITION - Co said record Q3 revenue and adjusted EBITDA were primarily driven by contributions from Sanity Group

  • INTERNATIONAL SALES - Co said higher proportion of international sales from Sanity Group helped boost adjusted gross margin

  • OPERATIONAL EFFICIENCIES - Co said improved operational efficiencies and targeted product portfolio changes supported Canadian market performance


Company press release: ID:nBw5cPj7Sa


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

C$105.78 mln

C$98.75 mln (5 Analysts)

Q3 Gross Revenue

C$145.07 mln

Q3 Net Income

C$105.54 mln

Q3 Adjusted EBITDA

C$13.41 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the healthcare facilities & services peer group is "buy"

  • Wall Street's median 12-month price target for Organigram Global Inc is C$3.25, about 127.3% above its August 10 closing price of C$1.43

  • The stock recently traded at 25 times the next 12-month earnings vs. a P/E of 20 three months ago


Reuters Recommended Reads

  • Aug 10 - Canadian cannabis producer Village Farms beats 'Q2 sales, EPS estimates on record yields, exports

  • Aug 10 - Canada's Cargojet Q2 revenue beats estimates

  • Aug 10 - SHF Holdings Q2 revenue rises 4.8%, net loss widens on deemed dividend


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Organigram Global

See all news